ES2870498T3 - Iloperidona para el tratamiento de esquizofrenia - Google Patents
Iloperidona para el tratamiento de esquizofrenia Download PDFInfo
- Publication number
- ES2870498T3 ES2870498T3 ES16710038T ES16710038T ES2870498T3 ES 2870498 T3 ES2870498 T3 ES 2870498T3 ES 16710038 T ES16710038 T ES 16710038T ES 16710038 T ES16710038 T ES 16710038T ES 2870498 T3 ES2870498 T3 ES 2870498T3
- Authority
- ES
- Spain
- Prior art keywords
- iloperidone
- dose
- daily
- patients
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117173P | 2015-02-17 | 2015-02-17 | |
| US201562172436P | 2015-06-08 | 2015-06-08 | |
| PCT/US2016/018316 WO2016134049A1 (en) | 2015-02-17 | 2016-02-17 | Iloperidone for the treatment of schizophrenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2870498T3 true ES2870498T3 (es) | 2021-10-27 |
Family
ID=55532275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16710038T Active ES2870498T3 (es) | 2015-02-17 | 2016-02-17 | Iloperidona para el tratamiento de esquizofrenia |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10441580B2 (enExample) |
| EP (1) | EP3258935B1 (enExample) |
| JP (1) | JP6885649B2 (enExample) |
| KR (1) | KR102870956B1 (enExample) |
| CN (2) | CN116211857A (enExample) |
| BR (1) | BR112017017608A2 (enExample) |
| CA (1) | CA2976383C (enExample) |
| ES (1) | ES2870498T3 (enExample) |
| WO (1) | WO2016134049A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
| WO2024137439A1 (en) * | 2022-12-19 | 2024-06-27 | Vanda Pharmaceuticals Inc. | Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia |
| CN121218989A (zh) | 2023-06-02 | 2025-12-26 | 万达制药公司 | 使用伊潘立酮的治疗方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050020632A1 (en) | 2001-08-31 | 2005-01-27 | Dominique Grimler | Optical isomers of an iloperidone metabolite |
| JP5067998B2 (ja) | 2001-10-30 | 2012-11-07 | ノバルティス アーゲー | イロペリドンおよび星形ポリマーのデポー製剤 |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| ES2825949T3 (es) | 2004-09-30 | 2021-05-17 | Vanda Pharmaceuticals Inc | Métodos para administrar iloperidona |
| EP2198049A1 (en) * | 2007-09-10 | 2010-06-23 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on snp genotype |
| SI2234617T2 (sl) | 2007-12-19 | 2025-05-30 | Janssen Pharmaceutica Nv | Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje |
| EP2430183B1 (en) * | 2009-05-15 | 2014-12-17 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
| CN104220074A (zh) | 2011-12-02 | 2014-12-17 | 大日本住友制药株式会社 | 鲁拉西酮新给药方案以及其用于治疗、预防和/或控制至少一种cns病症的用途 |
| CN108938632A (zh) | 2012-03-14 | 2018-12-07 | 万达制药公司 | 用于治疗精神疾病的伊潘立酮代谢物及其应用 |
| KR102121633B1 (ko) * | 2012-08-21 | 2020-06-10 | 세이지 테라퓨틱스, 인크. | 간질 또는 간질지속 상태를 치료하는 방법 |
-
2016
- 2016-02-17 BR BR112017017608-4A patent/BR112017017608A2/en not_active Application Discontinuation
- 2016-02-17 WO PCT/US2016/018316 patent/WO2016134049A1/en not_active Ceased
- 2016-02-17 ES ES16710038T patent/ES2870498T3/es active Active
- 2016-02-17 EP EP16710038.7A patent/EP3258935B1/en active Active
- 2016-02-17 CN CN202310398029.9A patent/CN116211857A/zh active Pending
- 2016-02-17 CA CA2976383A patent/CA2976383C/en active Active
- 2016-02-17 KR KR1020177026225A patent/KR102870956B1/ko active Active
- 2016-02-17 CN CN201680010479.4A patent/CN107249586A/zh active Pending
- 2016-02-17 JP JP2017543816A patent/JP6885649B2/ja active Active
- 2016-02-17 US US15/549,820 patent/US10441580B2/en active Active
-
2019
- 2019-09-06 US US16/562,548 patent/US10987346B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018505901A (ja) | 2018-03-01 |
| CN107249586A (zh) | 2017-10-13 |
| US10987346B2 (en) | 2021-04-27 |
| KR20170118830A (ko) | 2017-10-25 |
| JP6885649B2 (ja) | 2021-06-16 |
| US20190388412A1 (en) | 2019-12-26 |
| US10441580B2 (en) | 2019-10-15 |
| CN116211857A (zh) | 2023-06-06 |
| EP3258935A1 (en) | 2017-12-27 |
| KR102870956B1 (ko) | 2025-10-16 |
| CA2976383A1 (en) | 2016-08-25 |
| BR112017017608A2 (en) | 2018-05-08 |
| US20180021324A1 (en) | 2018-01-25 |
| HK1248551A1 (zh) | 2018-10-19 |
| WO2016134049A1 (en) | 2016-08-25 |
| CA2976383C (en) | 2023-05-23 |
| EP3258935B1 (en) | 2021-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3018635C (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| WO2013152105A1 (en) | Pharmaceutical compositions for combination therapy | |
| Blier et al. | Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder | |
| Rodrigues et al. | Antibiotic prophylaxis for third molar extraction in healthy patients: Current scientific evidence. | |
| ES2870498T3 (es) | Iloperidona para el tratamiento de esquizofrenia | |
| Gortney et al. | Neuroleptic malignant syndrome secondary to quetiapine | |
| C Nelson et al. | Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment | |
| WO2016172672A1 (en) | Method for treating suicidal ideation | |
| WO2021165472A1 (en) | Masitinib for the treatment of a multiple sclerosis patient subpopulation | |
| BR112014004339A2 (pt) | suspensão oral | |
| EP4262801A1 (en) | Masitinib for the treatment of alzheimer's disease | |
| HK1248551B (en) | Iloperidone for the treatment of schizophrenia | |
| PT1714647E (pt) | Utilização da agomelatina para a obtenção de medicamentos destinados ao tratamento das patologias bipolares | |
| Shah et al. | New oral anticoagulants in patients with atrial fibrillation | |
| Memary et al. | Bradycardia and Severe Bispectral Index Drop Following Femoral Nerve Block by Dexmedetomidine due to Accidental Vascular Puncture: A Case Report | |
| Medic | Carbamazepine/cefuroxime axetil/ketoprofen/lamotrigine/lansoprazole | |
| Willis et al. | P. 3. c. 044 Antipsychotic polypharmacy in a community psychiatric clinic | |
| UA95167U (uk) | Спосіб лікування невропатії лицевого нерва у дітей з використанням препаратів метаболічної дії |